ImmunityBio, Inc. (IBRX) Earnings History
Annual and quarterly earnings data from 2013 to 2024
Loading earnings history...
IBRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
IBRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -2334.2% | -2804.8% |
| 2023 | 100.0% | -58239.5% | -93761.4% |
| 2022 | 100.0% | -146374.2% | -173569.6% |
| 2021 | 100.0% | -35361.9% | -37129.6% |
| 2020 | 100.0% | -36509.1% | -36669.6% |
Download Data
Export IBRX earnings history in CSV or JSON format
Free sign-in required to download data
ImmunityBio, Inc. (IBRX) Earnings Overview
As of May 8, 2026, ImmunityBio, Inc. (IBRX) reported trailing twelve-month net income of -$349M, reflecting +46.1% year-over-year growth. The company earned $-0.37 per diluted share over the past four quarters, with a net profit margin of -2804.8%.
Looking at the long-term picture, IBRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
ImmunityBio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), FATE (-$136M net income, -2051.1% margin), CRIS (-$8M net income, -80.3% margin), IBRX has room to improve margins relative to the peer group. Compare IBRX vs NKTR →
IBRX Earnings vs Peers
Earnings metrics vs comparable public companies
IBRX Historical Earnings Data (2013–2024)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$414M | +29.1% | -$344M | $-0.62 | -2804.8% | -2334.2% |
| 2023 | -$583M | -40.0% | -$362M | $-1.15 | -93761.4% | -58239.5% |
| 2022 | -$417M | -20.1% | -$351M | $-1.04 | -173569.6% | -146374.2% |
| 2021 | -$347M | -56.3% | -$330M | $-0.89 | -37129.6% | -35361.9% |
| 2020 | -$222M | -237.2% | -$221M | $-0.59 | -36669.6% | -36509.1% |
| 2019 | -$66M | +31.6% | -$67M | $-0.42 | -152997.7% | -155597.7% |
| 2018 | -$96M | +0.2% | -$98M | $-0.30 | -204736.2% | -209338.3% |
| 2017 | -$96M | +20.2% | -$99M | $-0.30 | -214273.3% | -220266.7% |
| 2016 | -$121M | +49.0% | -$125M | $-0.37 | -274565.9% | -282954.5% |
| 2015 | -$237M | -3712.6% | -$239M | $-0.73 | -100371.2% | -101218.6% |
See IBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIBRX — Frequently Asked Questions
Quick answers to the most common questions about buying IBRX stock.
Is IBRX growing earnings?
IBRX EPS is $-0.37, with earnings growth accelerating to +46.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-349M.
What are IBRX's profit margins?
ImmunityBio, Inc. net margin is -2804.8%, with operating margin at -2334.2%. Below-average margins reflect competitive or cost pressures.
How consistent are IBRX's earnings?
IBRX earnings data spans 2013-2024. The accelerating earnings trend is +46.1% YoY. Historical data enables comparison across business cycles.